NEW YORK, March 28, 2017 /PRNewswire/ --
Focus is on the Biotechnology, a highly volatile and unpredictable sector
On Monday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. climbed 1.77%, ending the day at $39.12. The stock recorded a trading volume of 1.05 million shares. The Company's shares have advanced 16.78% in the last one month, 108.86% over the previous three months, and 74.33% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 21.81% and 59.53%, respectively. Moreover, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 63.78.
On February 28th, 2017, Portola Pharmaceuticals provided a corporate update and reported its financial results for Q4 2016 and year ended December 31st, 2016. Collaboration and license revenue in 2016 was $35.5 million compared with $12.1 million in 2015. For Q4 2016, total operating expenses were $68.9 million, research and development expenses were $56.0 million, and net loss was $53.8 million. PTLA complete research report is just a click away and free at:
Shares in Waltham, Massachusetts headquartered OvaScience Inc. ended the day 11.70% higher at $1.91. A total volume of 3.12 million shares was traded, which was above their three months average volume of 1.21 million shares. In the last month and the previous three months, the stock has surged 29.05% and 42.54%, respectively. Additionally, the Company's shares have advanced 24.84% in the previous one year. The stock is trading above its 50-day moving average by 23.51%. Furthermore, shares of OvaScience, which discovers, develops, and commercializes fertility treatment options for women worldwide, have an RSI of 73.52.
On March 02nd, 2017, OvaScience reported financial results and provided a business update for Q4 2016 and year ended December 31st, 2016. For Q4 2016, revenue was $121,000; net loss was $22.6 million; and research and development expense, excluding restructuring costs, was $4.7 million. For full year 2016, revenue was $653,000; net loss was $82.3 million; and research and development expense, excluding restructuring costs, was $21.6 million. The complimentary report on OVAS can be downloaded at:
At the close of trading on Monday, shares in Palo Alto, California headquartered Ocera Therapeutics Inc. finished 3.20% higher at $1.29 with a total trading volume of 772,795 shares. The stock has advanced 105.25% in the last one month. The Company's shares are trading above their 50-day moving average by 12.24%. Additionally, shares of Ocera Therapeutics, which operates as a clinical stage biopharmaceutical Company, have an RSI of 50.95.
On March 10th, 2017, Ocera Therapeutics announced updates to its clinical development programs and reported financial results for Q4 2016 and year ended December 31st, 2016. Revenue for the three and twelve months of full year 2016 was $512,000 and $609,000, respectively. Net loss for the three and twelve months of full year 2016 was $5.2 million and $26.9 million, respectively. Sign up for your complimentary research report on OCRX at:
Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s shares recorded a trading volume of 685,579 shares at the end of yesterday's session. The stock closed the day 0.97% higher at $9.36. The Company's shares have advanced 14.85% in the past month, 13.18% in the last three months, and 11.83% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.31% and 30.25%, respectively. Additionally, shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have an RSI of 57.22.
On March 15th, 2017, Ocular Therapeutix announced positive results of a patient experience study of DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use. The study, published in Patient Preference and Adherence, evaluated the overall patient experience and perceived value of DEXTENZA following cataract surgery. Get free access to your research report on OCUL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All